Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Alpha-Mannosidosis Clinical Trials Review, H2 2018 Report Featuring Chiesi Farmaceutici, Zymenex, Larix, Nuo Therapeutics, Fate Therapeutics & Cromsource - ResearchAndMarkets.com

April 4, 2019

DUBLIN--(BUSINESS WIRE)--Apr 4, 2019--The “Alpha-Mannosidosis Global Clinical Trials Review, H2, 2018” clinical trials has been added to ResearchAndMarkets.com’s offering.

“Alpha-Mannosidosis Global Clinical Trials Review, H2, 2018” provides an overview of Alpha-Mannosidosis clinical trials scenario. This report provides top line data relating to the clinical trials on Alpha-Mannosidosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.

The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). These reports are generated using a proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.


  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Key Topics Covered:

  1. List of Tables
  2. List of Figures
  3. Report Guidance
  4. Clinical Trials Report Coverage
  5. Clinical Trials by Region
  6. Clinical Trials and Average Enrollment by Country
  7. Top Five Countries Contributing to Clinical Trials in Europe
  8. Top Countries Contributing to Clinical Trials in North America
  9. Clinical Trials by G7 Countries: Proportion of Alpha-Mannosidosis to Genetic Disorders Clinical Trials
  10. Clinical Trials by Phase in G7 Countries
  11. Clinical Trials in G7 Countries by Trial Status
  12. Clinical Trials by Phase
  13. In Progress Trials by Phase
  14. Clinical Trials by Trial Status
  15. Clinical Trials by End Point Status
  16. Subjects Recruited Over a Period of Time
  17. Clinical Trials by Sponsor Type
  18. Prominent Sponsors
  19. Top Companies Participating in Alpha-Mannosidosis Therapeutics Clinical Trials
  20. Prominent Drugs
  21. Clinical Trial Profile Snapshots
  22. Appendix

Companies Mentioned

  • Chiesi Farmaceutici SpA
  • Zymenex AS
  • Larix A/S
  • Nuo Therapeutics Inc
  • Fate Therapeutics Inc
  • Cromsource Srl

For more information about this clinical trials report visit https://www.researchandmarkets.com/research/zwp9qc/global?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190404005422/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Clinical Trials,Endocrine and Metabolic Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 04/04/2019 08:54 AM/DISC: 04/04/2019 08:53 AM